success_jsonpCallback({"requestId":"index","data":[{"id":71373,"fileId":"734f9b367eda8cc30a6bcbb88ead420e","datestr":"20260915","docClassify":21,"parentType":0,"doctName":"MRI 医用影像行业研究报告：高端设备国产替代与精准诊疗驱动的百亿市场突围  头豹词条报告系列.pdf","docSummary":"磁共振成像（MRI）是一种非侵入性影像检查技术，广泛应用于人体多部位疾病诊断。随着技术迭代，智能化与多模态融合成为趋势，提高了诊疗效率。政策推动行业规范\n化，产业链协同与监管强化。三级医院是MRI主要市场，对高端设备需求突出，而二级医院市场在政策红利下增长迅速。未来，三级医院将继续推动MRI设备市场需求，而\n分级诊疗制度将促进二级医院及基层医疗机构对MRI设备的需求增长，为行业带来新的增长点。","docFormat":"pdf","uploader":"088dd0821a3e4999a5323c31f60185b2","uploadTime":1789457796000,"uploadName":"头豹研究院","docStatus":1,"docSize":5429199,"zhuanye":0,"zyzValue":0,"docSizeConvert":"5.18M","isKnowledgeTag":0,"docType":0,"sourceId":0,"sourceType":0,"agreeTime":1789528791000,"md5":"21a5a1fc4c068c393afb9852eeb33c65","docScore":0,"isFree":0,"isPreferential":0,"isTop":0,"isFirst":1,"shareCounts":0,"downCounts":1956,"vdownCounts":1956,"readCounts":2347,"praiseCounts":0,"collectCounts":0,"totalObtainScore":0,"originalUrl":"http://docs.cn-healthcare.com/sharedoc/src_files/20260915/734f9b367eda8cc30a6bcbb88ead420e.pdf","pdfUrl":"http://docs.cn-healthcare.com/sharedoc/src_files/20260915/734f9b367eda8cc30a6bcbb88ead420e.pdf","swfUrl":"http://docs.cn-healthcare.com/sharedoc/swf_files/20260915/734f9b367eda8cc30a6bcbb88ead420e.swf","thumbnail":"http://docs.cn-healthcare.com/sharedoc/swf_files/20260915/734f9b367eda8cc30a6bcbb88ead420e-thumb.png","totalPages":0,"docPayType":0,"isEbook":0,"download":1,"formFlag":0,"vipquanyi":1,"isvip":0,"vipPrice":0.0,"needlogin":0,"shidu":0,"renzhengtemp":0,"shenfenflag":0,"hegui":0,"renzhengCode":"1"},{"id":71372,"fileId":"6e16ea14e48a628d624f62c959d4b19d","datestr":"20260915","docClassify":225,"parentType":0,"doctName":"2025年中国生物细胞资源产业链洞察报告（一）细胞存储技术.pdf","docSummary":"政策监管:国家持续完善细胞治疗产品的临床研发与监管体系，着重强调产品的安全性、质量可控性与标准化管理，为行业提供了清晰的发展方向，鼓励产学研深度融合，加速临床转化与应用，为生物经济新模式的健康发展营造了有利环境。\n市场需求:中国人口结构老龄化加剧，年龄相关疾病防控需求显著提升，推动细胞资源存储的价值认知和再生医学的应用前景。同时，中国卫生总费用持续扩大，政府支出与社会投入不断增强，个人医疗负担逐步减轻\n宏观医疗卫生支出的结构优化为细胞存储这类预防性健康投资创造了良好的支付环境和市场接受度。技术研发:细胞存储已从早期低温保存逐步演进至多机制协同、多学科交叉的主动功能维持策略。低温保存与冷冻保存技术分别针对短期代谢稳态和长期冰晶损伤、氧化应激等多重挑战，发展出精细化、差异化的解决方案。竞争格局:中国细胞存储市场呈现多梯队分化特征。头部企业凭借先发优势、全国化布局和高水平建库质量引领行业向自动化、智能化与标准化方向发展;地方性机构则依托区域政策支持和本地资源，形成较强的区域影响力;第三梯队由大量新兴和跨界企业构成，业务模式多元但质量参差不齐，反映出行业仍在不断演进和规范之中。消费者在选择细胞存储服务时重点关注细胞处理技术、质量保障、品牌声誉与服务覆盖范围，价格并非唯一决策因素，中长期信任与安全性愈发重要。","docFormat":"pdf","uploader":"088dd0821a3e4999a5323c31f60185b2","uploadTime":1789457712000,"uploadName":"头豹研究院","docStatus":1,"docSize":1522298,"zhuanye":0,"zyzValue":0,"docSizeConvert":"1.45M","isKnowledgeTag":0,"docType":0,"sourceId":0,"sourceType":0,"agreeTime":1789528755000,"md5":"69d4a09795c35981b648f2dfca2ff6a8","docScore":450,"isFree":0,"isPreferential":0,"isTop":0,"isFirst":1,"shareCounts":0,"downCounts":1218,"vdownCounts":1218,"readCounts":1619,"praiseCounts":0,"collectCounts":0,"totalObtainScore":0,"originalUrl":"http://docs.cn-healthcare.com/sharedoc/src_files/20260915/6e16ea14e48a628d624f62c959d4b19d.pdf","pdfUrl":"http://docs.cn-healthcare.com/sharedoc/src_files/20260915/6e16ea14e48a628d624f62c959d4b19d.pdf","swfUrl":"http://docs.cn-healthcare.com/sharedoc/swf_files/20260915/6e16ea14e48a628d624f62c959d4b19d.swf","thumbnail":"http://docs.cn-healthcare.com/sharedoc/swf_files/20260915/6e16ea14e48a628d624f62c959d4b19d-thumb.png","totalPages":0,"docPayType":2,"isEbook":0,"download":1,"formFlag":0,"vipquanyi":1,"isvip":0,"vipPrice":0.0,"needlogin":0,"shidu":0,"renzhengtemp":0,"shenfenflag":0,"hegui":0,"renzhengCode":"1"},{"id":71371,"fileId":"537b7bcb790acf223a4c2a3a4b17caf4","datestr":"20260915","docClassify":225,"parentType":0,"doctName":"2025年中国免疫细胞治疗产品行业研究：百亿市场加速扩容，国产创新迈向全球引领.pdf","docSummary":"政策梳理:中国免疫细胞治疗产品行业的政策环境持续优化，国家通过《“十四五"生物经济发展规划》等顶层设计，明确将细胞治疗列为重点发展领域，并持续完善从研发、临床到上市的全生命周期监管体系和技术指导原则，为产品商业化提供了清晰的制度保障。近年来，政策进一步鼓励真实世界数据应用并加速审评审批，北京、上海等地也纷纷出台地方细则，推动形成区域创新高地，为产业孵化与集聚发展创造了有利条件。\n市场规模:行业呈现高速增长态势。中国市场规模从2019年的约15亿元增长至2023年的近55亿元，年复合增长率显著。这一增长主要得益于CAR-T产品在多发性骨髓瘤等血液肿瘤领域展现出的突出疗效，以及国内多款产品相继获批上市。预计到2030年，中国市场规模有望突破百亿美元。伴随医保动态谈判和多层次保障体系的推进，细胞治疗产品的可及性正逐步提升，未来市场渗透率有望进一步扩大。\n发展趋势:行业正聚焦突破实体瘤治疗等临床难题，TCR-T、CAR-NK等创新技术路径成为研发热点。降本增效是未来竞争核心，通用型细胞疗法及自动化工艺的开发将加速推进，推动治疗从“天价"走向可及。同时，资本将持续加持异体通用化、肿瘤微环境调控等前沿技术平台，引领产业进入新一轮发展期。AI辅助的靶点发现和\n智能化生产也有望重塑行业研发范式，提升创新效率和治疗精准度。","docFormat":"pdf","uploader":"088dd0821a3e4999a5323c31f60185b2","uploadTime":1789457636000,"uploadName":"头豹研究院","docStatus":1,"docSize":1825857,"zhuanye":0,"zyzValue":0,"docSizeConvert":"1.74M","isKnowledgeTag":0,"docType":0,"sourceId":0,"sourceType":0,"agreeTime":1789528720000,"md5":"37077cd945e9cdd0139920a29131c23e","docScore":450,"isFree":0,"isPreferential":0,"isTop":0,"isFirst":1,"shareCounts":0,"downCounts":1622,"vdownCounts":1622,"readCounts":1955,"praiseCounts":0,"collectCounts":0,"totalObtainScore":0,"originalUrl":"http://docs.cn-healthcare.com/sharedoc/src_files/20260915/537b7bcb790acf223a4c2a3a4b17caf4.pdf","pdfUrl":"http://docs.cn-healthcare.com/sharedoc/src_files/20260915/537b7bcb790acf223a4c2a3a4b17caf4.pdf","swfUrl":"http://docs.cn-healthcare.com/sharedoc/swf_files/20260915/537b7bcb790acf223a4c2a3a4b17caf4.swf","thumbnail":"http://docs.cn-healthcare.com/sharedoc/swf_files/20260915/537b7bcb790acf223a4c2a3a4b17caf4-thumb.png","totalPages":0,"docPayType":2,"isEbook":0,"download":1,"formFlag":0,"vipquanyi":1,"isvip":0,"vipPrice":0.0,"needlogin":0,"shidu":0,"renzhengtemp":0,"shenfenflag":0,"hegui":0,"renzhengCode":"1"},{"id":71370,"fileId":"3f9249dd2ce54cb3701bda3c758abe1d","datestr":"20260915","docClassify":252,"parentType":0,"doctName":"2025年中国过敏性疾病药物行业系列报告（一）：过敏性鼻炎生物制剂治疗进展与医保覆盖.pdf","docSummary":"治疗规范:过敏性鼻炎的常用治疗药物根据临床推荐等级分为一线、二线和三线用药。一线药物是临床首选包括鼻用糖皮质激素(如糠酸莫米松、布地奈德)、第二代口服及鼻用抗组胺药(如氯雷他定、西替利嗪)以及口服白三烯受体拮抗剂(如孟鲁司特钠)\n市场规模:中国过敏性疾病药物市场规模由2019年的44亿美元增加至2024年的81亿美元，年复合增速为12.9%,预计未来到2030年，市场规模将以19.0%的增速增加至229亿美元。其中，生物制剂从2019年的1亿美元增加至2024年的16亿美元，预计到2030年增加至124亿美元;小分子药物从2019年的43亿美元增加至2024年的65亿美元，预计到2030年增加至105亿美元。\n新药研发:生物制剂作为针对中重度过敏性疾病患者的靶向治疗方案，尤其适用于标准治疗反应不佳的人群。目前临床应用的主要药物包括度普利尤单抗(阻断IL-4Ra)、奥马珠单抗(阻断lgE)、美泊利珠单抗(阻断L-5)、瑞利珠单抗(阻断L-5R)及特泽鲁单抗(阻断TSLP)等。这些创新疗法通过精准干预关键炎症通路，可显著改善临床症状、减少鼻息肉体积并降低糖皮质激素使用剂量，对lgE水平升高、嗜酸性粒细胞增多或合并多器官受累的患者群体展现出显著疗效优势。然而，高昂的治疗成本及注射给药方式限制了其临床可及性，部分患者依从性较低。目前，部分新型生物制剂仍处于早期研发阶段，其长期疗效与安全性仍需通过大规模临床研究进一步验证","docFormat":"pdf","uploader":"088dd0821a3e4999a5323c31f60185b2","uploadTime":1789457500000,"uploadName":"头豹研究院","docStatus":1,"docSize":1676906,"zhuanye":0,"zyzValue":0,"docSizeConvert":"1.6M","isKnowledgeTag":0,"docType":0,"sourceId":0,"sourceType":0,"agreeTime":1789528614000,"md5":"57a5823d740fa6f1b9fad1b8323b1de4","docScore":450,"isFree":0,"isPreferential":0,"isTop":0,"isFirst":1,"shareCounts":0,"downCounts":1694,"vdownCounts":1694,"readCounts":2014,"praiseCounts":0,"collectCounts":0,"totalObtainScore":0,"originalUrl":"http://docs.cn-healthcare.com/sharedoc/src_files/20260915/3f9249dd2ce54cb3701bda3c758abe1d.pdf","pdfUrl":"http://docs.cn-healthcare.com/sharedoc/src_files/20260915/3f9249dd2ce54cb3701bda3c758abe1d.pdf","swfUrl":"http://docs.cn-healthcare.com/sharedoc/swf_files/20260915/3f9249dd2ce54cb3701bda3c758abe1d.swf","thumbnail":"http://docs.cn-healthcare.com/sharedoc/swf_files/20260915/3f9249dd2ce54cb3701bda3c758abe1d-thumb.png","totalPages":0,"docPayType":2,"isEbook":0,"download":1,"formFlag":0,"vipquanyi":1,"isvip":0,"vipPrice":0.0,"needlogin":0,"shidu":0,"renzhengtemp":0,"shenfenflag":0,"hegui":0,"renzhengCode":"1"},{"id":71369,"fileId":"51d40d575fb63691b8c7c3f2d14f2b55","datestr":"20260915","docClassify":252,"parentType":0,"doctName":"蚊媒病毒感染防治行业跟踪：从基孔肯雅热区域流行看公共卫生应对方案.pdf","docSummary":"蚊媒病毒感染是全球公共卫生的重要威胁，其传播媒介广泛、地域性强且受气候变化影响显著，中国南方及西南地区因生态多样性成为主要流行区域。随着城市化进程加快和跨境人口流动增加，蚊媒病毒传播风险持续上升，亟需系统性防控方案以平衡早期预警、精准诊疗和生态治理。当前中国蚊媒病毒防控体系正从传统被动响应转向主动监测与科技驱动模式，通过整合人工智能预警、基层能力强化和国际合作，逐步构建“防-控-治”一体化解决方案，但诊疗市场成熟度不足、区域资源分配不均等问题仍需突破。","docFormat":"pdf","uploader":"088dd0821a3e4999a5323c31f60185b2","uploadTime":1789457418000,"uploadName":"头豹研究院","docStatus":1,"docSize":2911689,"zhuanye":0,"zyzValue":0,"docSizeConvert":"2.78M","isKnowledgeTag":0,"docType":0,"sourceId":0,"sourceType":0,"agreeTime":1789528581000,"md5":"3de0a5dad8790ec41e3966b9ca51cbbd","docScore":800,"isFree":0,"isPreferential":0,"isTop":0,"isFirst":1,"shareCounts":0,"downCounts":1699,"vdownCounts":1699,"readCounts":2051,"praiseCounts":0,"collectCounts":0,"totalObtainScore":0,"originalUrl":"http://docs.cn-healthcare.com/sharedoc/src_files/20260915/51d40d575fb63691b8c7c3f2d14f2b55.pdf","pdfUrl":"http://docs.cn-healthcare.com/sharedoc/src_files/20260915/51d40d575fb63691b8c7c3f2d14f2b55.pdf","swfUrl":"http://docs.cn-healthcare.com/sharedoc/swf_files/20260915/51d40d575fb63691b8c7c3f2d14f2b55.swf","thumbnail":"http://docs.cn-healthcare.com/sharedoc/swf_files/20260915/51d40d575fb63691b8c7c3f2d14f2b55-thumb.png","totalPages":0,"docPayType":2,"isEbook":0,"download":1,"formFlag":0,"vipquanyi":1,"isvip":0,"vipPrice":0.0,"needlogin":0,"shidu":0,"renzhengtemp":0,"shenfenflag":0,"hegui":0,"renzhengCode":"1"}]})